JAK2 Mutation: Clinical Trials

1 trial for JAK2 Mutation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Completed 1

Follow JAK2 Mutation: new trials by email Literature Review of JAK2 Mutation trials Research Report on JAK2 Mutation

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET)
Phase 2CompletedOttawa Hospital Research Institute442021-02-172024-05-29

Narrower conditions

Myeloproliferative Disorders (1)  ·  Polycythemia Vera (1)  ·  Primary Myelofibrosis (1)  ·  Thrombocythemia, Essential (1)  ·  Venous Thromboembolism (1)

Broader conditions

Blood Coagulation Disorders (1)  ·  Blood Platelet Disorders (1)  ·  Bone Marrow Diseases (1)  ·  Bone Marrow Neoplasms (1)  ·  Cardiovascular Diseases (1)  ·  Embolism and Thrombosis (1)  ·  Hematologic Diseases (1)  ·  Hematologic Neoplasms (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Hemorrhagic Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Thrombocytosis (1)  ·  Thromboembolism (1)  ·  Vascular Diseases (1)

Interventions

Aspirin (1)  ·  Tablets (1)  ·  apixaban (1)

Sponsors

Ottawa Hospital Research Institute (1)

Countries

Canada (1)

Top investigators

Aurelien Delluc, MD, PhD (1)  ·  Miriam Kimpton, MD (1)